Privium Fund Management B.V. Purchases 102,850 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Privium Fund Management B.V. increased its position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 34.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 397,650 shares of the biotechnology company's stock after acquiring an additional 102,850 shares during the period. Rocket Pharmaceuticals comprises approximately 1.1% of Privium Fund Management B.V.'s portfolio, making the stock its 19th biggest holding. Privium Fund Management B.V. owned about 0.44% of Rocket Pharmaceuticals worth $4,998,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the company. First Turn Management LLC lifted its position in shares of Rocket Pharmaceuticals by 10.8% in the third quarter. First Turn Management LLC now owns 621,306 shares of the biotechnology company's stock worth $11,476,000 after buying an additional 60,317 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in shares of Rocket Pharmaceuticals in the third quarter worth $636,000. Jennison Associates LLC grew its stake in shares of Rocket Pharmaceuticals by 33.2% in the third quarter. Jennison Associates LLC now owns 40,740 shares of the biotechnology company's stock worth $752,000 after acquiring an additional 10,162 shares during the last quarter. Intech Investment Management LLC bought a new position in Rocket Pharmaceuticals during the third quarter worth $527,000. Finally, Charles Schwab Investment Management Inc. grew its position in Rocket Pharmaceuticals by 3.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 569,814 shares of the biotechnology company's stock worth $10,524,000 after purchasing an additional 20,322 shares during the last quarter. Institutional investors and hedge funds own 98.39% of the company's stock.

Remove Ads

Rocket Pharmaceuticals Price Performance

NASDAQ RCKT traded up $0.11 during midday trading on Friday, hitting $8.43. The company had a trading volume of 3,251,822 shares, compared to its average volume of 1,002,793. The company has a market capitalization of $898.89 million, a PE ratio of -3.07 and a beta of 1.03. Rocket Pharmaceuticals, Inc. has a twelve month low of $8.06 and a twelve month high of $27.71. The company has a current ratio of 6.05, a quick ratio of 6.05 and a debt-to-equity ratio of 0.06. The firm has a 50-day moving average price of $9.87 and a 200-day moving average price of $13.61.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The biotechnology company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.06. As a group, analysts anticipate that Rocket Pharmaceuticals, Inc. will post -2.83 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Needham & Company LLC cut their price objective on shares of Rocket Pharmaceuticals from $52.00 to $42.00 and set a "buy" rating for the company in a research report on Friday, February 28th. Jefferies Financial Group initiated coverage on Rocket Pharmaceuticals in a research report on Wednesday, December 18th. They issued a "buy" rating and a $29.00 price objective for the company. Canaccord Genuity Group dropped their price objective on Rocket Pharmaceuticals from $39.00 to $36.00 and set a "buy" rating for the company in a report on Monday, March 3rd. Scotiabank increased their price target on shares of Rocket Pharmaceuticals from $51.00 to $52.00 and gave the company a "sector outperform" rating in a research report on Monday, March 3rd. Finally, The Goldman Sachs Group reduced their price target on shares of Rocket Pharmaceuticals from $29.00 to $15.00 and set a "neutral" rating for the company in a report on Monday, March 3rd. One investment analyst has rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $43.00.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.